Lack of consistent sex differences in d-amphetamine-induced dopamine release measured with [18F]fallypride PET
Sex differences in the dopaminergic response to psychostimulants could have implications for drug abuse risk and other psychopathology involving the dopamine system, but human data are limited and mixed.
Here, we sought to investigate sex differences in dopamine release after oral d-amphetamine administration.
We used [18F]fallypride positron emission tomography (PET) to measure the change in dopamine D2/3 receptor availability (%ΔBPND, an index of dopamine release) between placebo and d-amphetamine sessions in two independent datasets containing a total of 39 females (on either hormonal birth control n = 18, postmenopausal n = 10, or studied in the first 10 days of their menstrual cycle n = 11) and 37 males.
Using both a priori anatomical regions of interest based on previous findings and voxelwise analyses, we failed to consistently detect broad sex differences in d-amphetamine-induced dopamine release. Nevertheless, there was limited evidence for greater right ventral striatal dopamine release in young adult males relative to similarly aged females, but this was not consistently observed across samples. Plasma estradiol did not correlate with dopamine release and this measure did not differ in females on and off hormonal birth control.
While our finding in young adults from one dataset of greater %ΔBPND in males is partially consistent with a previously published study on sex differences in d-amphetamine-induced dopamine release, our data do not support the presence of consistent widespread sex differences in this measure of dopamine release.
Keywords(up to 10): Sex differences Dopamine PET D2/3 receptor availability Dopamine release d-amphetamine
This work was supported by AG043458 (DHZ & GRS-L) and AG042596 (GRS-L) from the National Institute on Aging and DA019670 (DHZ), DA041157 (CTS), and DA036979 (LCD) from the National Institute on Drug Abuse.
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
- First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition. (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, New YorkGoogle Scholar
- Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, Newberg A, Battistini M (2004) Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry 12:621–630CrossRefPubMedGoogle Scholar
- Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034–1057CrossRefPubMedGoogle Scholar
- Riccardi P, Zald D, Li R, Park S, Ansari MS, Dawant B, Anderson S, Woodward N, Schmidt D, Baldwin R, Kessler R (2006) Sex differences in amphetamine-induced displacement of [(18)F]fallypride in striatal and extrastriatal regions: a PET study. Am J Psychiatry 163:1639–1641CrossRefPubMedGoogle Scholar
- Samanez-Larkin GR, Buckholtz JW, Cowan RL, Woodward ND, Li R, Ansari MS, Arrington CM, Baldwin RM, Smith CE, Treadway MT, Kessler RM, Zald DH (2013) A thalamocorticostriatal dopamine network for psychostimulant-enhanced human cognitive flexibility. Biol Psychiatry 74:99–105CrossRefPubMedGoogle Scholar
- Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23(Suppl 1):S208–S219CrossRefPubMedGoogle Scholar
- Smith CT, Dang LC, Buckholtz JW, Tetreault AM, Cowan RL, Kessler RM, Zald DH (2017) The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum. Transl Psychiatry 7:e1091CrossRefPubMedPubMedCentralGoogle Scholar
- Vernaleken I, Peters L, Raptis M, Lin R, Buchholz HG, Zhou Y, Winz O, Rosch F, Bartenstein P, Wong DF, Schafer WM, Grunder G (2011) The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab 31:1958–1966CrossRefPubMedPubMedCentralGoogle Scholar